The Prognostic Value of Epigenetic Silencing of p16 Gene in NSCLC Patients: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Lou Qian, Zhang ^a   Rong, Yin ^a   Ming, Li ^a   Xin, Yang ^a   Feng, Jiang ^a   Lin, Xu ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; METHYLATION; OVERALL SURVIVAL; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; GENES, P16; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS;

EID: 84872838573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054970     Document Type: Article

References (49)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Sapari NS, Loh M, Vaithilingam A, Soong R, (2012) Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One 7: e36275.
3. Zhang B, Zhu W, Yang P, Liu T, Jiang M, et al. (2011) Cigarette smoking and p16INK4alpha gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis. PLoS One 6: e28882.
4. Lu F, Zhang HT, (2011) DNA methylation and nonsmall cell lung cancer. Anat Rec (Hoboken) 294: 1787-1795.
5. Serrano M, Hannon GJ, Beach D, (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
6. Voorhoeve PM, Agami R, (2003) The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4: 311-319.
7. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
8. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
9. Kang HJ, Kim EJ, Lee KM, Roh MS, Kwak JY, et al. (2012) Quantitative analysis of multiple gene promoter methylation in Korean non-small cell lung cancer patients and its association study with cancer risk factor and survival. Molecular and Cellular Toxicology 8: 25-34.
10. Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl MP, et al. (2011) A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. Journal of Thoracic Oncology 6: 1649-1657.
11. Sasaki H, Hikosaka Y, Kawan O, Moiyama S, Yan M, et al. (2010) Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients. Oncology Letters 1: 283-287.
12. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, et al. (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126: 1630-1639.
13. Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, et al. (2009) Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. International Journal of Oncology 35: 1201-1209.
14. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, et al. (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56: 115-123.
15. Ota N, Kawakami K, Okuda T, Takehara A, Hiranuma C, et al. (2006) Prognostic significance of p16INK4a hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Research 26: 3729-3732.
16. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, et al. (2005) Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 130: 1378.
17. Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, et al. (2005) Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. International Journal of Cancer 114: 400-405.
18. Wang J, Lee JJ, Wang L, Liu DD, Lu C, et al. (2004) Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clinical Cancer Research 10: 6119-6125.
19. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF, (2004) Hypermethylation of FHIT as a Prognostic Marker in Nonsmall Cell Lung Carcinoma. Cancer 100: 1472-1477.
20. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, et al. (2003) Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clinical Cancer Research 9: 1370-1375.
21. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, et al. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255.
22. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, et al. (2001) p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Research 61: 3419-3424.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
24. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
25. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
26. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
27. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
28. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629-634.
29. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, et al. (2004) The relationship between aberrant methylation and survival in non-small-cell lung cancers. British Journal of Cancer 91: 771-774.
30. Kim YT, Lee SH, Sung SW, Kim JH, (2005) Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Annals of Thoracic Surgery 79: 1180-1188.
31. Safar AM, Spencer H, 3rd, Su X, Coffey M, Cooney CA, et al (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11: 4400-4405.
32. Tanaka R, Wang D, Morishita Y, Inadome Y, Minami Y, et al. (2005) Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103: 608-615.
33. Gu J, Berman D, Lu C, Wistuba II, Roth JA, et al. (2006) Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clinical Cancer Research 12: 7329-7338.
34. Sugio K, (2006) The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma: Epigenetic silencing, clinical features, and prognostic significance. Cancer 106: 2190-2199.
35. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, et al. (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58: 131-138.
36. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, et al. (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
37. Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, et al. (2009) Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis. International Journal of Oncology 34: 805-812.
38. Kim JS, Kim JW, Han J, Shim YM, Park J, et al. (2006) Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 66: 4049-4054.
39. Bradly DP, Buckingham L, Coon J, Liptay M, Bonomi P, et al. (2010) Age-related CDKN2A (p16) promoter methylation and outcome in surgically treated stage I-II non-small cell lung cancer patients. Laboratory Investigation 90: 399A.
40. Shimamoto T, Ohyashiki JH, Hirano T, Kato H, Ohyashiki K, (2004) Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. Oncol Rep 12: 389-395.
41. Fu J, Zhang J, Zhang HW, (2003) Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer. Zhonghua bing li xue za zhi Chinese journal of pathology 32: 133-136.
42. Niklinska W, Chyczewski L, Laudanski J, Chyczewska E, Niklinski J, (2001) Detection of p16 abnormalities in early-stage non-small cell lung cancer. Folia Histochemica et Cytobiologica 39: 30-32.
43. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
44. Kato A, Shimizu K, Shimoichi Y, Fujii H, Honoki K, et al. (2006) Aberrant DNA methylation of E-cadherin and p16 genes in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinog 45: 106-111.
45. Honoki K, Tsujiuchi T, Mori T, Yoshitani K, Tsutsumi M, et al. (2004) Expression of the p16INK4a gene and methylation pattern of CpG sites in the promoter region in rat tumor cell lines. Mol Carcinog 39: 10-14.
46. Patel AC, Anna CH, Foley JF, Stockton PS, Tyson FL, et al. (2000) Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. Carcinogenesis 21: 1691-1700.
47. Esteller M, (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440.
48. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, et al. (2009) Methylated genes as new cancer biomarkers. Eur J Cancer 45: 335-346.
49. Stewart LA, Parmar MK, (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341: 418-422.